Drug intelligence / Profile preview

YHC1156

Development stage: Preclinical
Lead developer: Yuhan
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

YHC1156 is an investigational small molecule targeted protein degrader (TPD) being developed by Yuhan Corporation for the treatment of solid tumors. As a synthetic drug candidate, it is designed to selectively induce the degradation of specific proteins involved in tumor growth and survival, potentially addressing targets that are considered "undruggable" by traditional occupancy-based inhibitors. YHC1156 is part of Yuhan's strategic expansion into the TPD field, which the company has prioritized as a next-generation growth engine following the success of its EGFR inhibitor lazertinib. The drug is currently in the preclinical discovery stage of development.

Beyond the preview

Go deeper on YHC1156.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YHC1156.

Explore the full profile